Anakinra, a recombinant human interleukin-1 receptor antagonist offers a new 
potent treatment for rheumatoid arthritis(RA). It is administered as a daily 
single subcutaneous injection. Recent randomized, double-blind, 
placebo-controlled trials revealed that anakinra significantly reduces the signs 
and symptoms of RA, reduces joint destruction, and is safe and tolerated. It was 
also revealed that anakinra is more potent when used in combination with 
methotrexate.